| FDA Approves Updated Label For Merck's Vytorin - Update - NASDAQ |
|
|
NASDAQ Merck noted that in the Study of Heart and Renal Protection or SHARP, Vytorin 10/20 mg lowered LDL cholesterol or bad cholesterol in patients with moderate to severe chronic kidney disease, and major vascular events were reduced in the treatment group ... New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes |